Romilkimab - Sanofi

Drug Profile

Romilkimab - Sanofi

Alternative Names: Bispecific IL4/IL13 antibody - sanofi-aventis; IL4/IL13 bi-specific monoclonal antibody - sanofi-aventis; SAR 156597; SUB33159

Latest Information Update: 05 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator sanofi-aventis
  • Developer Sanofi
  • Class Bispecific antibodies; Monoclonal antibodies
  • Mechanism of Action Interleukin 13 inhibitors; Interleukin 4 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Idiopathic pulmonary fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Systemic scleroderma
  • Discontinued Idiopathic pulmonary fibrosis

Most Recent Events

  • 31 Jul 2018 Sanofi announces intention to submit regulatory application for Systemic Scleroderma in 2022
  • 18 May 2018 Efficacy and safety data from a phase II trial in Idiopathic pulmonary fibrosis presented at the 114th International Conference of the American Thoracic Society (ATS-2018)
  • 14 Aug 2017 Sanofi completes a phase II trial in Idiopathic pulmonary fibrosis (In the elderly, In adults) in USA, Canada, Czech Republic and Denmark, Argentina, Chile, Colombia, France, Germany, Greece, Israel, Italy, Mexico, Spain, Turkey, Australia, South Korea, Portugal and United Kingdom (NCT02345070)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top